Deadline: 22-May-25
Pfizer Inc. and Arvinas are collaborating to provide grant support for continuing professional education in metastatic Breast Cancer (mBC).
Area of Interest
- This competitive grant program seeks to support independent medical education activities focused on the evolving treatment landscape for patients with ER+/HER2- mBC.
- Applicants are encouraged to identify and address the educational needs of healthcare professionals related to novel treatments in the evolving clinical landscape of ER+/HER2- mBC. Proposed educational activities should focus on increasing the understanding of emerging mechanisms of action (MOA) of novel agents, practice-changing clinical updates for mBC and how to incorporate them safely and effectively for appropriate patients – particularly in the post-CDK4/6 inhibitor(s) setting.
- Projects that will be considered for grant support will focus on one or more of the following:
- Increasing understanding of emerging and novel therapeutic agents in the evolving treatment landscape of ER+/HER2- mBC
- Exploring the current unmet needs in ER+/HER2- mBC, including the relevance and applicability of biomarker testing
- Increasing understanding of differentiated MOA of emerging therapies including proteolysis targeting chimera estrogen receptor (PROTAC ER) degraders from that of other endocrine therapies (e.g., SERDs)
- Increasing understanding of the latest clinical data updates relevant to the treatment of patients with ESR1 mutated ER+/HER2- mBC
Funding Information
- Individual projects requesting up to $175,000 will be considered although smaller, focused projects with lower budgets are preferred.
- The estimated total available budget related to this RFP is $730,000.
Duration
- Anticipated approximate Project Start and End Dates: July 2025 – June 2026 (15-month maximum execution timeline, i.e., from contract execution to provision of final outcomes).
Target Audience and Geographic Scope
- The intended learner audience should include medical oncologists and other healthcare professionals involved in breast cancer patient care.
- The geographic scope of this RFP is global with the United States as the primary priority.
Eligibility Criteria
- The following types of organizations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Please note:
- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
- For projects offering continuing education credit, the requesting organization must be accredited.
For more information, visit Pfizer.
